Melanotan II Peptide: Tanning Claims, Side Effects and Safety Risks
Melanotan II peptide guide covering tanning claims, human evidence, mole changes, priapism reports, regulator warnings and safety limits.
Melanotan II is the tanning peptide that keeps returning in Reddit threads, TikTok clips, bodybuilding forums and peptide vendor pages. The pitch is simple: a synthetic melanocortin peptide that darkens skin with less UV exposure. The evidence and safety picture are not simple.
The strongest human tanning evidence is a tiny 1996 phase 1 study in three male volunteers. The safety literature includes dermatology reviews, case reports of mole changes, ischemic priapism reports and regulator warnings about unapproved products sold online. That is enough to make Melanotan II a real research topic, but not enough to make it a safe cosmetic shortcut.
For PeptideStat context, compare this guide with PT-141 bremelanotide, another melanocortin peptide with a much clearer regulated label. For peptide basics, see what peptides are, peptide half-life explained, peptide storage, bacteriostatic water basics, and how to inject peptides safely. Those pages explain concepts. They are not instructions to use an unapproved tanning peptide.
This guide is educational and not medical advice. New or changing moles, unusual pigmentation, priapism, neurologic symptoms, severe nausea, chest symptoms or reactions after an unapproved product need clinician evaluation. Melanotan II is not a substitute for sunscreen, dermatology care or an approved prescription product.
Melanotan II At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic cyclic alpha-MSH analog that activates melanocortin receptors. |
| Main online use | Artificial tanning, often by injection or nasal spray from unapproved sources. |
| Human evidence | One very small phase 1 tanning study plus case reports and reviews. |
| Approved status | No FDA-approved Melanotan II drug label for tanning or any other use. |
| Related approved drug | Afamelanotide, sold as Scenesse, is an approved implant for erythropoietic protoporphyria. |
| Main safety issues | Product quality, mole changes, skin-cancer concern, nausea, flushing, fatigue, priapism and uncertain long-term risk. |
What Melanotan II Does
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. The mechanism of interest is melanocortin receptor activation. MC1 receptor activation on melanocytes can increase melanin production, which is why the compound is discussed as a tanning agent.
Melanotan II is not selective only for skin pigmentation. Melanocortin receptors also appear in pathways related to appetite, sexual function and central nervous system signaling. That helps explain why early human work and case reports mention nausea, appetite effects, yawning, stretching, erections and priapism rather than only skin darkening.
The related drug comparison is useful but often misused. Scenesse is afamelanotide, not Melanotan II. DailyMed lists Scenesse as an FDA-approved afamelanotide implant with a prescription drug label for increasing pain-free light exposure in adults with erythropoietic protoporphyria. That does not make Melanotan II an approved cosmetic tanning drug.
What Human Evidence Shows
The classic Melanotan II human study was a pilot phase 1 trial in three healthy male volunteers. Participants received alternating saline or Melanotan II subcutaneous injections on weekdays over two weeks, with dose escalation.
The result was enough to show biological activity. Two subjects had increased pigmentation by reflectance and visual assessment after dosing ended. The same abstract reported mild nausea at most dose levels, grade 2 somnolence and fatigue at the highest dose in one subject, and spontaneous penile erections lasting one to five hours in temporal association with yawning and stretching.
That study does not answer the questions people ask online in 2026. It does not establish long-term safety, cancer risk, safe product sourcing, nasal-spray use, repeated seasonal cycles, use in women, use in teenagers, use with tanning beds, use in people with atypical moles or use in people with cardiovascular or urologic risk.
| Evidence type | What it supports | What it does not support |
|---|---|---|
| 1996 phase 1 study | Melanotan II can increase pigmentation in a tiny human sample. | Long-term cosmetic use or broad safety. |
| Dermatology review | Unregulated alpha-MSH analog use is associated with concerning skin and product-quality issues. | Proof that every mole change is caused by Melanotan II. |
| Case reports | Priapism, atypical nevi and other events have been reported after use. | Population-level risk rates. |
| Regulator warnings | Online products can be illegal, unapproved and quality-uncertain. | A clinical dosing framework. |
Skin, Mole And Cancer Questions
Skin cancer is the central concern in consumer discussions. The honest answer is specific: case reports and reviews raise concern, but they do not prove a clean cause-and-effect link between Melanotan II and melanoma.
That does not make the concern trivial. Dermatology case reports describe new or changing atypical melanocytic nevi after melanotan use. One teenage patient with familial atypical mole and malignant melanoma syndrome developed marked tanning, multiple dark nevi and an enlarging nevus after Melanotan 2 injections and UV tanning studio exposure. A review of unregulated alpha-MSH analogues noted increasing case reports of melanocytic changes and several melanoma reports during or shortly after melanotan use, while also stating that conclusive evidence was lacking.
The practical problem is that Melanotan II is often paired with UV exposure to deepen the tan. UV exposure is an established skin-cancer risk. Darkening moles can also make self-monitoring harder, especially for people with many nevi, freckles, prior skin cancer, a family history of melanoma or atypical mole syndrome.
Regulators take the issue seriously. A 2026 Therapeutic Goods Administration media release stated that there were no products containing Melanotan II on the Australian Register of Therapeutic Goods or approved for supply in Australia. It also described Melanotan II as a prescription-only medicine in Australia and warned that unapproved therapeutic goods may pose significant health risks.
Priapism And Systemic Side Effects
Melanotan II's sexual-function effects are not a rumor invented by forums. They are consistent with melanocortin biology and appear in early human observations and case reports.
BMJ Case Reports described acute priapism after subcutaneous melanotan use. A Sexual Medicine case report described acute ischemic priapism after Melanotan II injection that required operative management after initial measures failed. These are case reports, not incidence studies, but priapism is a medical emergency because prolonged ischemia can damage erectile tissue.
Other reported or regulator-listed adverse effects include nausea, vomiting, headache, loss of appetite, facial redness, fatigue, somnolence and product quality risks. FDA's 2026 safety-risk materials for compounding list Melanotan II among withdrawn nominated substances and state that case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.
That FDA page is not a consumer dosing label. It is a safety-risk signal that the agency lacks the kind of product, route and exposure information needed to treat compounded Melanotan II as a routine medicine.
How To Read Melanotan II Claims
| Claim | Better question |
|---|---|
| "Sunless tan" | Is the person still using UV exposure or tanning beds to intensify the color? |
| "Safer than tanning" | What evidence compares long-term Melanotan II use with standard sun protection? |
| "Same family as Scenesse" | Is it the FDA-approved afamelanotide implant or unapproved Melanotan II? |
| "Only cosmetic" | What about nausea, blood pressure-like symptoms, priapism and neurologic case reports? |
| "Lab tested" | Was sterility, identity, purity, concentration and contaminant testing batch-specific and independent? |
Reddit and forums show why this topic has demand: people ask about nasal spray versus injections, mole darkening, nausea, erections, appetite suppression, whether sunscreen is still needed, how long color lasts and how to interpret skin checks while using it. Those questions are useful for article planning. They are not proof of safety or effectiveness.
Where It Fits
Melanotan II belongs near the melanocortin and peptide-safety discussion, not beside ordinary cosmetics. It is closer mechanistically to PT-141 bremelanotide than to collagen creams or GHK-Cu hair content, but its regulatory status is very different from Vyleesi or Scenesse.
It also differs from peptides such as KPV or thymosin alpha-1, where the marketing drift is usually inflammation or immune modulation. Melanotan II has visible cosmetic appeal, which can make risk tolerance worse because the desired result is obvious while the long-term safety questions are delayed.
If a source presents Melanotan II as a tanning hack, a sunscreen replacement or a casual aesthetic stack, it is skipping the most important context: the compound is unapproved, product quality is uncertain, and dermatology and urology case reports are part of the evidence record.
Bottom Line
Melanotan II has real biological activity. A tiny human phase 1 study reported increased pigmentation, and the mechanism makes sense for a melanocortin peptide.
The safety and regulatory story is the reason for caution. Melanotan II is not an FDA-approved tanning drug, not equivalent to Scenesse and not a replacement for sunscreen. Case reports describe mole changes and priapism, regulator sources warn about unapproved online products, and long-term cosmetic-use data are not strong enough to support confident safety claims.
References
Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Hjuler KF, Lorentzen HF. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.
Cousen P, Colver G, Helbling I. Atypical melanocytic naevi following melanotan injection.
Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan.
Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism.
TGA. Individual issued 27 infringement notices for allegedly supplying Melanotan II.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
DailyMed. SCENESSE- afamelanotide implant.